Advagen Holdings Inc. to acquire stake in GEn1E Lifesciences Inc.

Advagen Holdings Inc. ("Advagen"), a wholly owned subsidiary of Rubicon Research Limited ("Company"), has entered into a definitive agreement with GEn1E Lifesciences Inc. ("Gen1E"), to acquire Series Prime Preferred Stock in tranches, for a total consideration of up to USD 3 million.

The transaction is a minority investment in Gen1E relating to the development of pharmaceutical products.

Gen1E is a pharmaceutical company with a pipeline of product candidates under development. GEn1E is based in Palo Alto, California, with a laboratory in Mountain View, California, USA.

Shares of Rubicon Research Limited was last trading in BSE at Rs. 611.85 as compared to the previous close of Rs. 604.75. The total number of shares traded during the day was 15964 in over 873 trades.

The stock hit an intraday high of Rs. 618.50 and intraday low of 606.25. The net turnover during the day was Rs. 9793981.00.

Source : Equity Bulls

Keywords

RubiconResearch INE506V01022 Pharmaceuticals AdvagenHoldingsInc GEn1ELifesciencesInc Investment